trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Ozempic causes cancer

the verdict
REFUTED
the evidence says no
Recorded sources
0 sources for · 6 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Ozempic causes cancer?

No. Large-scale clinical, real-world, and systematic review data do not support the claim that Ozempic (or other GLP-1 receptor agonists) causes cancer, with multiple comprehensive studies showing no increased risk of thyroid or colorectal malignancies.

Verdict: REFUTED · 0 sources for, 6 against · Last checked

The analysis

The retrieved literature consistently evaluates the purported link between GLP-1 receptor agonists (such as semaglutide and liraglutide) and cancer risk. Multiple large clinical trial analyses, real-world database evaluations, systematic reviews, and target trial emulations (e.g., papers 1, 3, 4, 7, 9) find no causal link or increased incidence of thyroid or colorectal cancers associated with these medications. While a few pharmacovigilance reports or isolated case presentations exist (papers 3, 5, 7), authors explicitly note these are insufficient to establish causation and are outweighed by robust epidemiological and clinical trial data. Therefore, the claim that Ozempic causes cancer is refuted by the balance of high-quality evidence.

Evidence against · 6
Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.
2026
Evaluated clinical trials, post-marketing data, and commercial databases and found no association between GLP-1 receptor agonist use and thyroid cancer risk.
Get citation
T, V., M, S., VR, A., S, D., JP, D., CTP, K., S, R., FL, R., & L, H. (2026). Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.. doi.org. https://doi.org/10.1111/dom.70291

See more details
More against · 5
Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence.
2026
Concluded that individual case reports of papillary thyroid carcinoma during semaglutide therapy do not establish causation and that available human data support safety regarding thyroid cancer.
Get citation
J, H., A, H., L, N., O, H., & F, H. (2026). Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence.. doi.org. https://doi.org/10.1007/s42000-026-00801-3

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.
2026
Found no increased risk of thyroid tumors or thyroid cancer with GLP-1 receptor agonist use in large-scale cohort studies.
Get citation
S, S., EO, E. O., A, M., MA, M. E., TM, M. H., M, A., SO, F., SA, M. I., HO, A. M., & AHM, A. (2026). Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.. doi.org. https://doi.org/10.7759/cureus.108005

Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
2026
Identified some safety signals via pharmacovigilance but noted that disproportionality reports cannot establish incidence or causality.
Get citation
S, X. (2026). Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.. doi.org. https://doi.org/10.1111/dom.71138

Papillary Thyroid Carcinoma Following Semaglutide Therapy for Metabolic Syndrome: A Case Presentation and Review of Current Evidence
2026
Stated that a reported case of papillary thyroid carcinoma following semaglutide therapy highlights a clinical scenario rather than providing evidence of causation.
Get citation
J, H., A, H., L, N., OM, H., & FH, H. (2026). Papillary Thyroid Carcinoma Following Semaglutide Therapy for Metabolic Syndrome: A Case Presentation and Review of Current Evidence. doi.org. https://doi.org/10.21203/rs.3.rs-8344892/v1

Glucagon-Like Peptide 1 Receptor Agonists and Early Colorectal Neoplasia: A Colonoscopy-Anchored Target Trial Emulation
2026
Associated GLP-1 RA initiation with a lower hazard of incident benign colorectal neoplasms compared to active comparators.
Get citation
AT, K., Y, Z., & RS, M. (2026). Glucagon-Like Peptide 1 Receptor Agonists and Early Colorectal Neoplasia: A Colonoscopy-Anchored Target Trial Emulation. doi.org. https://doi.org/10.21203/rs.3.rs-9727823/v1

Related receipts
Receipt History
first checked05 Aug 2026
judged → REFUTED · 405 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work